Clinical Trials Directory

Trials / Unknown

UnknownNCT05544123

The Treatment Situation of Chinese County Population With Breast Cancer

A Multi-center, Observational Study to Describe the Treatment Situation of Chinese County Population With HER2+ & HR+/HER2- Breast Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
2,500 (estimated)
Sponsor
The First Affiliated Hospital of Xinxiang Medical College · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is a multi-center, non-interventional, prospective observational study which enrols 2500 breast cancer patients from China county area. The purpose of this study is to be aware of the real-world data of the current breast cancer diagnosis and treatment model in the county. It aims to understand the gap between the county and the SOC in the diagnosis and treatment.

Detailed description

The study is a multi-center, non-interventional, prospective observational study which enrols 2500 breast cancer patients from China county area. The patients will be divided into four cohorts by HR/HER2 status and early/late stage without prespecified minimum or maximum limit of patient number for each cohort. The potential study subjects will be identified by the investigators by face-to-face visit. During this process approximately 2500 subjects will be enrolled in 1 year. All subjects will be sign informed consent and recorded for demographic characteristics, medical history, treatment history, treatment hospital, pathologic diagnosis, receptor status, therapeutic regimen, etc at the beginning of enrollment. Normally, there will be 4 visits for EBC and 6 visits for ABC in hospitals during yearlong follow-up period. All visits are according to the standard frequency of clinical follow-up. If the patient does not come to the hospital for follow-up on a regular basis, we will follow-up by telephone inquiries, etc.The potential study subjects will be identified by the investigators by face-to-face visit. During this process approximately 2500 subjects will be enrolled in 1 year. All subjects will be sign informed consent and recorded for demographic characteristics, medical history, treatment history, treatment hospital, pathologic diagnosis, receptor status, therapeutic regimen, etc at the beginning of enrollment. Normally, there will be 4 visits for EBC and 6 visits for ABC in hospitals during yearlong follow-up period. All visits are according to the standard frequency of clinical follow-up. If the patient does not come to the hospital for follow-up on a regular basis, we will follow-up by telephone inquiries, etc.

Conditions

Interventions

TypeNameDescription
OTHERpathological stagebreast cancer molecular subtyping and pathological TNM stage

Timeline

Start date
2022-09-29
Primary completion
2023-08-01
Completion
2024-09-01
First posted
2022-09-16
Last updated
2023-01-04

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05544123. Inclusion in this directory is not an endorsement.